Nkarta

Enrollment open for Ntrust-2 trial testing NKX019 cell therapy in AAV, systemic sclerosis, and idiopathic inflammatory myopathy. NKX019 targets B-cells to potentially slow harmful immune reactions. Trial follows FDA clearance, with preliminary results expected next year.

DelveInsight's report highlights a robust lupus nephritis pipeline with 30+ companies developing 35+ therapies, including key players like AstraZeneca and Novartis. Promising therapies like Anifrolumab and Ianalumab are in various clinical phases, with recent updates from companies like Adicet Bio and Kyverna Therapeutics. The report provides comprehensive insights into the pipeline, therapeutic assessments, and market dynamics.

The 'Lupus Nephritis - Pipeline Insight, 2024' report by ResearchAndMarkets.com provides a comprehensive overview of the current and future prospects of Lupus Nephritis treatments. It details the pipeline landscape, including disease overview, treatment guidelines, and assessments of emerging drugs like QLG1074, ADX-097, KYV-101, CABA-201, and NKX019. The report highlights ongoing R&D efforts, key collaborations, and trends in drug development, focusing on novel approaches to improve disease management. It also covers clinical trial stages, route of administration, and molecule types, identifying unmet needs and the impact of emerging therapies.

Autolus Therapeutics announces FDA approval of AUCATZYL® (obe-cel) for adult B-cell Acute Lymphoblastic Leukemia, triggering $30m milestone payment from Blackstone. Obe-cel marketing authorizations are under review with MHRA and EMA. The company also appointed Matthias Will M.D. as Chief Development Officer and reported financial results for Q3 2024, with a net loss of $82.1m.

NK cell therapy, a promising cancer treatment, sees robust R&D with 140+ companies developing 160+ therapies. Key players include Amgen, Innate Pharma, Nektar Therapeutics, and others. Promising therapies like Bemarituzumab, Monalizumab, and NKTR-225 are in various clinical phases. Recent milestones include Immunitybio's CAR-NK cell therapy for NHL, Nkarta's NKX019 for AAV, and KGen Biotech's SNK01 advancing to Phase II.

Nkarta reports financial results for Q3 2024, focusing on NKX019 for autoimmune diseases; enrollment ongoing in Ntrust-1 and investigator-sponsored clinical trial (IST); Ntrust-2 enrollment expected by year-end 2024; preliminary clinical data from Ntrust-1 and Ntrust-2 planned for 2025; no further NKX019 development in lymphoma planned; cash balance of $405.3 million expected to fund operations into late 2027.